{"schema_version":"secwatch.filing_event.v1","accession":"0001193125-23-158979","form_type":"8-K","ticker":"CPRX","cik":"0001369568","company_name":"CATALYST PHARMACEUTICALS, INC.","filed_at":"2023-06-01T23:59:59+00:00","discovered_at":"2026-05-14T18:03:38.590045+00:00","generated_at":"2026-06-14T09:10:25.042138+00:00","sec_items":["8.01","9.01"],"event_type":"other_material","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Catalyst reaffirms FY2023 revenue $375M-$385M; non-GAAP net income $195M-$205M","bullets":["Reaffirms full-year 2023 total revenue guidance of $375M to $385M, 75-80% YoY increase.","FIRDAPSE net product revenue guided $245M-$255M, up 17% vs. 2022.","FYCOMPA net product revenue forecast at ~$130M for 11 months after Jan. 24 acquisition.","Non-GAAP net income forecast of $195M to $205M for full-year 2023."],"urls":{"canonical":"https://secwatch.observer/filing/0001193125-23-158979","json":"https://secwatch.observer/filing/0001193125-23-158979.json","markdown":"https://secwatch.observer/filing/0001193125-23-158979.md","text":"https://secwatch.observer/filing/0001193125-23-158979.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523158979/0001193125-23-158979-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1369568/000119312523158979/d463989d8k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-14T09:10:25.042138+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}